June 25, 2002 -- The U.S. Food and Drug Administration (FDA) has approved a once-a-week dose of risedronate (Actonel) for the prevention and treatment of postmenopausal osteoporosis. The new dose ...

The patient is advised not to eat or lie down at least 30 minutes after the tablet. Dosage & When it is to be taken PO- Adult: Osteoporosis- The recommended dose is 5 mg/day. For postmenopausal ...

Learn everything you need to know about Risedronate-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions ...

Oral bisphosphonates must be taken after an overnight fast either once weekly (alendronate at a dose of 70 mg or risedronate at a dose of 35 mg), once monthly (ibandronate at a dose of 150 mg or ...

Women who received at least one dose of either risedronate or placebo were included in the analysis. Women who discontinued treatment before the end of the three-year treatment period were ...

If treatment with glucocorticoids is continued for a period of 3 months then, regardless of the dose, the patient should receive one of four treatment options: alendronate, risedronate ...

There were no statistically significant differences in BMD increases between the risedronate 150 mg once monthly and the 5 mg daily dose groups at 12 months at all sites. In the study, the ...

The efficacy of one infusion of Reclast 5 mg versus oral daily doses of risedronate 30 mg for two months was evaluated in two identical six-month, randomized, double-blind trials. Therapeutic ...

To determine whether use of the bisphosphonate risedronate can decrease amount of bone loss in adults with ALL/LL receiving chemotherapy with high-dose corticosteroids, Maria E. Cabanillas ...

A dose of 2.5 mg per day of risedronate was administered orally for 24 months in the risedronate administration group. Statistical analyses were performed using commercially available software ...

which evaluated the efficacy of 5 mg oral risedronate daily for the prevention of bone loss at the spine and hip in patients receiving high-dose prednisolone therapy (>0.5 mg/kg/day). Risedronate ...

There were no statistically significant differences in BMD increases between the risedronate 150 mg once monthly and the 5 mg daily dose groups at 12 months at all sites. In the study, the ...